The effect of bronchial hyperreactivity on the quality of life of patients with chronic obstructive pulmonary disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. In chronic obstructive pulmonary disease (COPD), in addition to clinical and functional parameters, quality of life (QOL) is a very important characteristic that affects many features of the course of the disease. Therefore, it seems important to study various factors that have impact on QOL. There is no evidence of a relationship between QOL and bronchial hyperreactivity (BHR) in COPD. Objective. Assessment of the impact of BHR on QOL of COPD patients. Methods. Clinical and functional indicators, QOL parameters depending on the level of bronchial reactivity were analyzed in 139 patients with moderate COPD. According to the level of bronchial reactivity, COPD patients were divided into 2 groups: group 1 - 95 people with BHR, group 2 - 44 patients without BHR. Both groups did not differ significantly in the severity of bronchial obstruction. Results. For all domains of the questionnaire, QOL was worse by 14.6-25.2 points (p<0.05) in patients with BHRcompared with patients without BHR. The adverse modifying effect of BHR on the QOL of COPD patients was confirmed by a correlation dependence (p -0,47 to -0.51; p<0.001). The results of the study showed that the dominant factor determining QOL of COPD patients is dyspnea. The second most important factor deteriorating QOL is the level of bronchial reactivity, which largely determines the severity of dyspnea in COPD patients. Conclusion. BHR has a pronounced negative effect on the QOL of COPD patients, worsening the subjective assessment of the disease symptoms, the psycho-emotional status and perception of the disease by patient. Reducing the level of BHR should be considered as one of the most important therapeutic targets for COPD therapy, aimed at improving the QOL of COPD patients.

Full Text

Restricted Access

About the authors

I. N Trofimenko

Irkutsk State Medical Academy of Postgraduate Education - Branch of Russian Medical Academy of Continuous Professional Education

Email: tin11@mail.ru
MD, Associate Professor, Department of Clinical Allergology and Pulmonology

B. A Chernyak

Irkutsk State Medical Academy of Postgraduate Education - Branch of Russian Medical Academy of Continuous Professional Education

References

  1. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva, World Health Organization, 2018. Available from: https://www.who.int/news-room/fact-sheets/ detail/the-top-W-causes-of-death.
  2. Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci. (Lond). 2017;131(13):1541-58. Doi: 10.1042/ CS20160487.
  3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2019. Available from: https://www. goldcopd.org.
  4. Van Schayck C.P, Dompeling E., Molema J., et al. Does bronchial hyperresponsiveness precede or follow airway obstruction in asthma or COPD? Neth J Med. 1994;45(4):145-53.
  5. Dosman J.A., Gomez S.R., Zhou C. Relationship between airways responsiveness and the development of chronic obstructive pulmonary disease. Med Clin North Am. 1990;74(3):561-69.
  6. Cockcroft D.W, Wenzel S. Airway hyperresponsiveness and chronic obstructive pulmonary disease outcomes. J Allergy Clin Immunol. 2316;138(6): 1580-81. doi: 13.1316/j.jaci.2316.36.339.
  7. Marcon A., Locatelli F., Keidel D., et al. Airway responsiveness to methacholine and incidence of COPD: an international prospective cohort study. Thorax. 2018;73(9):825-32. Doi: 10.1136/ thoraxjnl-2017-211289.
  8. Van den Berge M., Vonk J.M., Gosman M., et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J. 2012;40(5):1098-105. doi: 10.1183/09031936.00169711.
  9. Yang S. C., Lin B. Y. Comparison of Airway Hyperreactivity in Chronic Obstructive Pulmonary Disease and Asthma. Chang Gung Med J. 2010;33:515-23.
  10. Трофименко И.Н., Черняк Б.А. Бронхиальная гиперреактивность как фенотипическая характеристика хронической обструктивной болезни легких. Пульмонология. 2311;4:49-23. Doi: org/13.18393/3869-3189-2311-3-4-49-23.
  11. Трофименко И.Н., Черняк Б.А. Клиникофункциональные особенности и бронхопро-тективный эффект М-холинолитиков у больных ХОБЛ с бронхиальной гиперреактивностью. Фарматека. 2017;14(347):12-7.
  12. Hospers J.J., Postma D.S., Rijcken B., et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2330;326:1313-7.
  13. Jones PW., Rennard S., Tabberer M., et al. Interpreting patient-reported outcomes from clinical trials in COPD: a discussion. Int J. Chron Obstruct Pulmon Dis. 2016;11:3069-78. doi: 13.2147/COPD.S117378.
  14. Cazzola M., Hanania N.A., MacNee W., et al. A review of the most common patient-reported outcomes in COPD-revisiting current knowledge and estimating future challenges. Int J. Chron Obstruct PulmonDis. 2312;13:722-38. doi: 10.2147/COPD. S77368.
  15. Bringsvor H.B., Langeland E., Oftedal B.F., et al. Qual. Life Res. 2019;28(267): 1-11. Doi: org/10.1007/ s11136-319-32231-8.
  16. Gulsvik A., Refvem O.K. Ascoring system on respiratory symptoms. Eur Respir J. 1988;1: 428-32.
  17. Klein G., Kohler D., Bauer C.P. Standartization of inhalation challenges for measuring the unspecific bronchial inhalation challenge by reservuar-method. Pneumologie. 1991;42:63-4.
  18. Стандартизация легочных функциональных тестов. Пер. с англ. под ред. А.Г. Чучалина. Пульмонология (приложение). 1993;60-9.
  19. Трофименко И.Н., Черняк Б.А. Предикторы тяжелой одышки у больных ХОБЛ средней степени тяжести. Пульмонология. 2314;2:22-9. Doi: org/13.18393/3869-3189-2314-3-2-22-29. [Trofimenko I.N., Chernyak B.A. Predictors of severe dyspnea in patients with moderate-to-severe chronic obstructive pulmonary disease. Russian Pulmonology. 2014;2:22-9. (InRuss.)]. Поступила / Received: 23.09.2019 Принята в п

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies